HemoslL AcuStar HIT-lgG(PF-4). Part Number: 0009800127. in vitro diagnostic Recall
HemoslL AcuStar HIT-lgG(PF-4). Part Number: 0009800127. in vitro diagnostic
FDA recall Class I
Ongoing
FDA lists this Class I recall for HemoslL AcuStar HIT-lgG(PF-4). Part Number: 0009800127. in vitro diagnostic. Review the affected identifiers, reported reason and manufacturer instructions below.
Recall at a glance
- Recall number
- Z-0001-2027
- Recall classification
- Class I
- Enforcement status
- Ongoing
- Initiation date
- Sep 3, 2026
- FDA report date
- Oct 21, 2026
- Quantity in commerce
- 434 units
- Distribution
- See key details
- FDA cause
- Under Investigation by firm
What is being recalled?
HemoslL AcuStar HIT-lgG(PF-4). Part Number: 0009800127. in vitro diagnostic
The retrieved code information does not contain explicit model/GTIN pairs that this publication can reliably map.
Search FDA identifier text
Search a model, catalog, lot or UDI value exactly as printed in FDA’s product description or code information.
This search checks only the FDA product description and code information displayed on this page. It does not decode a UDI, normalize GTIN lengths or establish a relationship between separately listed codes.
FDA code information
Part Number: 0009800127. UDI-DI: 08426951126545. Lot Number (Expiration Date): B40005 (01/16/2027), B38062 (11/01/2026).
Why was this product recalled?
Potential for invalid calibration curve or negative mean bias of up to 47% with patient samples.
These are potential consequences described in the source. The recall reason does not establish how many injuries or incidents occurred.
What actions did Instrumentation Laboratory take?
Instrumentation Laboratory notified consignees on about 09/03/2026 via emailed and mailed URGENT MEDICAL DEVICE REALL letter. Consignees were made aware of the issue and hazard involved. They were instructed to check inventory for affected lots, destroy any remaining product following each facility's standard procedures, and document the destruction on the enclosed Urgent Mandatory Response Tracking Form, including quantity destroyed and date of destruction. Consignees were asked to identify an alternative method for HIT antibody testing as a supply interruption is expected and work local Werfen representatives for guidance and transition support. Consignees were also requested to inform all laboratory personnel of the notification, forward the notification to all affected departments and locations within each facility, retain a copy of the notification for records and complete and return the Urgent Mandatory Response Tracking Form within 10 days of receipt even if there is no remaining inventory. On 09/29/2026, an expanded URGENT MEDICAL DEVICE RECALL Notification was sent to consignees through registered mail or email. The updated notification informed consignees of additional lot numbers affected. Instructions remained the same.
Read the manufacturer action recorded by FDARecall timeline
Recall initiated by firm
FDA classification recorded
FDA notice posted
FDA enforcement report date
Related FDA submissions
No submission number with an exact verified relationship is linked in the retrieved recall notice.
FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.
Source and update history
- FDA recall notice Z-0001-2027
- openFDA enforcement record · Source release Nov 11, 2026 · Retrieved Nov 19, 2026
- openFDA device recall record · Source release Nov 14, 2026 · Retrieved Nov 19, 2026
- FDA enforcement data
First stored snapshot of this source.
- FDA device-recall notice
First stored snapshot of this source.
The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.
Our data sources and methodology